- Home
- TXMD vs BIAF Comparison
TXMD vs BIAF Comparison
Compare TXMD & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- BIAF
- Stock Information
- Founded
- TXMD 2008
- BIAF 2014
- Country
- TXMD United States
- BIAF United States
- Employees
- TXMD N/A
- BIAF N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TXMD Health Care
- BIAF Health Care
- Exchange
- TXMD Nasdaq
- BIAF Nasdaq
- Market Cap
- TXMD 12.8M
- BIAF 14.5M
- IPO Year
- TXMD N/A
- BIAF 2022
- Fundamental
- Price
- TXMD $1.06
- BIAF $0.68
- Analyst Decision
- TXMD
- BIAF Strong Buy
- Analyst Count
- TXMD 0
- BIAF 1
- Target Price
- TXMD N/A
- BIAF $6.00
- AVG Volume (30 Days)
- TXMD 852.1K
- BIAF 313.4K
- Earning Date
- TXMD 11-12-2024
- BIAF 11-14-2024
- Dividend Yield
- TXMD N/A
- BIAF N/A
- EPS Growth
- TXMD N/A
- BIAF N/A
- EPS
- TXMD N/A
- BIAF N/A
- Revenue
- TXMD $1,596,000.00
- BIAF $9,367,785.00
- Revenue This Year
- TXMD $605.07
- BIAF $285.51
- Revenue Next Year
- TXMD $1.11
- BIAF $20.05
- P/E Ratio
- TXMD N/A
- BIAF N/A
- Revenue Growth
- TXMD N/A
- BIAF 2813.87
- 52 Week Low
- TXMD $0.70
- BIAF $0.66
- 52 Week High
- TXMD $2.75
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- TXMD 44.74
- BIAF 26.89
- Support Level
- TXMD $0.99
- BIAF $0.67
- Resistance Level
- TXMD $1.14
- BIAF $1.01
- Average True Range (ATR)
- TXMD 0.27
- BIAF 0.08
- MACD
- TXMD -0.00
- BIAF -0.01
- Stochastic Oscillator
- TXMD 20.69
- BIAF 4.29
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.